US 11,612,562 · Application 16/008,486 · Granted Mar 28, 2023
US 11,612,562
Solution preparation containing stabilized antibody
Estimated expiration
January 20, 2031
4y 135d remaining
- Could not fetch continuity data for application PCTJP2011050911: Resource not found (404)
Earliest effective filing
Jan 20, 2011
+ 20 years
Jan 20, 2031
PTA +0d
Jan 20, 2031
TD applied
Jan 20, 2031
Final
Jan 20, 2031
This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included. Terminal disclaimers can affect PTA (In re Cellect, LLC).
Calculation details
Base term
- Filing date
- June 14, 2018
- Earliest effective filing
- January 20, 2011
- Issue date
- March 28, 2023
- PTA
- 0 days
- Base expiry (before PTA)
- January 20, 2031
January 20, 2011 + 20 years = January 20, 2031
- Divisional of application 13/522,848, filed Oct 2, 2012, issued as US 10,022,319
- National stage entry of application PCTJP2011050911, filed Jan 20, 2011
- National stage entry of application PCTJP2011050911, filed Jan 20, 2011
Terminal disclaimers
TD caps expiration to January 20, 2031
US 6,663,007
Could not resolve calculation details
US 10,759,870· Application 16/099,341Capping patent
Multispecific antigen-binding molecules having blood coagulation factor viii (fviii) cofactor function-substituting activity and pharmaceutical formulations containing such a molecule as an active ingredient
- Filing date
- Nov 6, 2018
- Earliest effective filing
- Sep 27, 2018
- Issue date
- Sep 1, 2020
- PTA
- 0 days
- Calculated expiration
- Sep 27, 2038
National stage entry of PCTJP2018035832, filed Sep 27, 2018
Sep 27, 2018 + 20y = Sep 27, 2038
US 9,334,331· Application 13/885,421Capping patent
Bispecific antibodies
- Filing date
- Aug 30, 2013
- Earliest effective filing
- Nov 17, 2011
- Issue date
- May 10, 2016
- PTA
- +376 days
- Calculated expiration
- Nov 27, 2032
National stage entry of PCTJP2011076486, filed Nov 17, 2011
Nov 17, 2011 + 20y + 376d PTA = Nov 27, 2032
US 11,612,562· Application 16/008,486(from application 16/008,486)Capping patent
Solution preparation containing stabilized antibody
- Filing date
- Jun 14, 2018
- Earliest effective filing
- Jan 20, 2011
- Issue date
- Mar 28, 2023
- PTA
- 0 days
- Calculated expiration
- Jan 20, 2031
Divisional of 13/522,848, filed Oct 2, 2012, issued as US 10,022,319
National stage entry of PCTJP2011050911, filed Jan 20, 2011
National stage entry of PCTJP2011050911, filed Jan 20, 2011
Jan 20, 2011 + 20y = Jan 20, 2031
US 12,460,014· Application 16/093,495(from application 16/093,495)
Antibody-containing preparation
- Filing date
- Oct 12, 2018
- Earliest effective filing
- Apr 27, 2017
- Issue date
- Nov 4, 2025
- PTA
- +342 days
- Calculated expiration
- Apr 4, 2038
National stage entry of PCTJP2017016658, filed Apr 27, 2017
Apr 27, 2017 + 20y + 342d PTA = Apr 4, 2038
Notes (1)
- [TD_REFS_TRUNCATED] Found 7 TD references; resolving first 5 only
Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated
The prosecution record for your AI
Application 16/008,486 · US 11,612,562
You have the date. Your AI can have the file.
PatentReply compiles the prosecution history behind US 11,612,562: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.
One public application a month is free. The first compile takes a few minutes.
Strategy and filing changes require your approval.
Permanent link
www.patentreply.ai/tools/patent-expiration/US11612562Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.